Insider Selling: AtriCure (NASDAQ:ATRC) Insider Sells $271,140.00 in Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 4,519 shares of the stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $60.00, for a total transaction of $271,140.00. Following the transaction, the insider directly owned 142,745 shares of the company’s stock, valued at $8,564,700. This represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

• On Tuesday, September 8th, Salvatore Privitera sold 3,657 shares of AtriCure stock. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00.
• On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The shares were sold at an average price of $52.50, for a total value of $407,557.50.

AtriCure Stock Performance

NASDAQ ATRC traded up $0.81 on Thursday, hitting $60.77. 1,304,939 shares of the company’s stock were exchanged, compared to its average volume of 868,582. The firm has a market cap of $3.09 billion, a price-to-earnings ratio of 289.39 and a beta of 1.26. The firm’s 50-day moving average price is $46.26 and its two-hundred day moving average price is $35.07. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $61.70. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The firm had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same period in the previous year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts expect that AtriCure, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in AtriCure in the 2nd quarter valued at about $125,198,000. Bank of America Corp DE acquired a new position in AtriCure during the second quarter worth about $24,465,000. Grandeur Peak Global Advisors LLC acquired a new position in AtriCure during the second quarter worth about $16,435,000. Osterweis Capital Management Inc. acquired a new position in AtriCure during the second quarter worth about $14,028,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of AtriCure in the second quarter valued at about $9,388,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ATRC. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Stifel Nicolaus set a $65.00 price objective on shares of AtriCure in a research note on Thursday, September 17th. Piper Sandler boosted their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. UBS Group lowered their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Finally, Zacks Research lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.30.

AtriCure Company Profile

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.